A Phase I Study of INCB062079 in Patients with Advanced Liver Cancer and Other Solid Tumors

Full Title

A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Purpose

The purpose of this study is to determine the highest dose of the investigational drug INCB062079 that can be given safely in patients with advanced liver cancer and other solid tumors that have continued to grow despite treatment and cannot be surgically removed. INCB062079 is designed to work by blocking a protein pathway that cancer cells use to grow called FGF19. Laboratory studies have shown that INCB062079 can inhibit cancer cell growth and spread. It is given orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced cancer of the liver (hepatocellular carcinoma), bile duct (cholangiocarcinoma), esophagus, nasopharynx, or ovaries that is inoperable and has continued to grow despite prior treatment.
  • Patients must recover from the serious side effects of previous therapies before entering the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. James Harding at 646-888-4314.

Protocol

18-006

Phase

I

Investigator

Co-Investigators